SynthesisThe Cochrane database of systematic reviews2010
Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus.
Synthesis in The Cochrane database of systematic reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01589445. Cited by 166 papers, 14 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.
A Randomized Trial of the Effect of Continuous Glucose Monitoring (CGM) in Individuals With Type 1 Diabetes Treated With Multiple Daily Insulin Injections (MDI)
Efficiency Assessment of the Structured Education Program for Type 1 Diabetes Patients on Insulin Pump Therapy
Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump: A Comparison of Insulin Degludec to Continuous Subcutaneous Infusion of Insulin Aspart for Basal Insulin Delivery in Type 1 Diabetes
Who cites it
166 citing papers in PubMed, 14 syntheses or guidelines pooled it, 403 citations in OpenAlex.
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- RT-CGM in conjunction with CSII vs MDI in optimizing glycaemic control in T1DM: Systemic review and meta-analysis.Endocrinology, diabetes & metabolism · 2022Pooled it
- Tissue Response to Subcutaneous Infusion Catheter.Journal of diabetes science and technology · 2020Pooled it
- Safety of Ramadan fasting in young patients with type 1 diabetes: A systematic review and meta-analysis.Journal of diabetes investigation · 2019Pooled it
- Pooled it
- Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association.Diabetes care · 2018Guideline
- Different insulin types and regimens for pregnant women with pre-existing diabetes.The Cochrane database of systematic reviews · 2017Pooled it
- Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.The Cochrane database of systematic reviews · 2014Pooled it
- Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.The Cochrane database of systematic reviews · 2014Pooled it
- The evidence base for diabetes technology: appropriate and inappropriate meta-analysis.Journal of diabetes science and technology · 2013Pooled it
- Diabetes: glycaemic control in type 1.BMJ clinical evidence · 2011Pooled it
- Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2008Pooled it
- Rosiglitazone for type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2007Pooled it
- Pioglitazone for type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2006 · on this mapPooled it
- An Investigation Into Local Infusion Site Pain After Infusion of Ultra Rapid Lispro Excipients Across Sites and Depths.Journal of diabetes science and technology · 2024Trial
- Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2.Diabetes, obesity & metabolism · 2021Trial
- A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).Diabetes, obesity & metabolism · 2019Trial
- Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial.Medical decision making : an international journal of the Society for Medical Decision Making · 2018Trial
- Hypoglycaemia incidence and recovery during home use of hybrid closed-loop insulin delivery in adults with type 1 diabetes.Diabetes, obesity & metabolism · 2018Trial
- A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3).Diabetes technology & therapeutics · 2018Trial
106 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 1 diabetes is a metabolic disorder resulting from a defect in insulin secretion. Onset of type 1 diabetes mellitus may occur at any age and it is one of the most common chronic diseases of childhood and adolescence. Since there are no interventions known to prevent onset, it is vital that effective treatment regimes are available. Glycaemic control is maintained by replacement of insulin and may be in the form of 'conventional' insulin therapy (multiple injections per day) or continuous subcutaneous insulin infusion (CSII).
objectivesTo assess the effects of CSII compared to multiple insulin injections (MI) in people with type 1 diabetes mellitus. SEARCH STRATEGY: Studies were obtained from electronic searches of The Cochrane Library, MEDLINE, EMBASE and CINAHL. SELECTION CRITERIA: Studies were included if they were randomised controlled trials comparing CSII with three or more insulin injections per day (MI) in people with type 1 diabetes mellitus. DATA COLLECTION AND ANALYSIS: Two authors independently assessed risk of bias and extracted characteristics of included studies. Authors contacted study investigators to obtain missing information. Generic inverse variance meta-analyses using a random-effects model were performed. MAIN
resultsTwenty three studies randomised 976 participants with type 1 diabetes to either intervention. There was a statistically significant difference in glycosylated haemoglobin A1c (HbA1c) favouring CSII (weighted mean difference -0.3% (95% confidence interval -0.1 to -0.4). There were no obvious differences between the interventions for non-severe hypoglycaemia, but severe hypoglycaemia appeared to be reduced in those using CSII. Quality of life measures suggest that CSII is preferred over MI. No significant difference was found for weight. Adverse events were not well reported, no information is available on mortality, morbidity and costs. AUTHORS'
conclusionsThere is some evidence to suggest that CSII may be better than MI for glycaemic control in people with type 1 diabetes. Non-severe hypoglycaemic events do not appear to be reduced with CSII. There is insufficient evidence regarding adverse events, mortality, morbidity and costs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.